MASSDEVICE ON CALL — Medtronic (NYSE:MDT) this week announced that it’s bringing its Viva cardiac resynchronization therapy-pacemaker to the market in India, a country where Medtronic is banking on significant growth.

The Viva CRT pacemaker features proprietary AdaptivCRT software that automatically adjusts to patient’s heart rhythms to provide customized therapy. Clinical trials of AdaptivCRT devices have reported that the technology helps increase patients’ therapy response rate, lower heart failure hospitalizations and reduce risk of death and risk of developing atrial fibrillation.

"This personalized therapy is likely to reduce the need for the patient to be frequently hospitalized and the menace of stroke which needs emergency medical attention," Medtronic India cardiac & vascular group president Shamik Dasgupta told PharmaBiz.com. "Both these are significant issues in India and will prove to be of great value to patients."

India is a major strategic target for Medtronic, which has put major skin in breaching the hemodialysis market there as well as to establish a footprint in diabetes and heart disease.

 What to do with medical apps calling themselves toys?
There are a slew of apps with purported medical purposes that get away with untested claims by adding disclaimers that (barely) warn users that the product is for "entertainment" purposes only.  
Read more

 FDA stays lax on mobile medical app makers
The FDA updates its plans for regulating mobile medical apps, largely reiterating its previous hands-off philosophy.  
Read more

 ConforMIS touts new knee studies
Massachusetts orthopedics maker ConforMIS announced findings from 2 new studies showing that its iTotal customized knee implants beat off-the-shelf devices.
Read more

 Bringing iPhone to clinical trials
LabStyle Innovations president & CEO Erez Raphael offers his insight on 5 ways that smartphones could streamline and simplify clinical testing.
Read more